Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.80 |
| ▸ | CSF1R | P07333 | 5/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | BRAF | P15056 | 2/20 | 0.71 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.68 |
| ▸ | KIT | P10721 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15529261 | 0.90 | RXFP1 (1.00) | MEN1KMT2ATSHRRXFP1CSF1R | |
| SCHEMBL24448272 | 0.88 | KMT2A (0.77) | MEN1KMT2ATSHRRXFP1CSF1R | |
| SCHEMBL13540540 | 0.88 | MEN1 (0.78) | MEN1KMT2ATSHRRXFP1CSF1R | |
| SCHEMBL2565097 | 0.86 | KMT2A (0.76) | MEN1KMT2ATSHRRXFP1CSF1R | |
| SCHEMBL3486022 | 0.85 | RXFP1 (0.79) | MEN1KMT2ATSHRRXFP1MAPT | |
| SCHEMBL5665029 | 0.85 | EPHX2 (0.76) | MEN1KMT2ATSHRCSF1RBRAF | |
| SCHEMBL6054935 | 0.84 | MEN1 (0.73) | MEN1KMT2ATSHRRXFP1CSF1R | |
| SCHEMBL4286068 | 0.84 | MAPT (0.94) | MEN1KMT2ATSHRRXFP1MAPT | |
| SCHEMBL17992413 | 0.84 | BRAF (1.00) | MEN1KMT2ATSHRRXFP1CSF1R | |
| SCHEMBL14214468 | 0.84 | KMT2A (0.72) | MEN1KMT2ATSHRRXFP1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| EP-1259487-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2002-11-27 | — | — | EP | claimed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | claimed |
| WO-2001055114-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2001-08-02 | — | — | WO | claimed |
| EP-4504174-A2 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | Purdue Research Foundation (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196930-A2 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | PURDUE RESEARCH FOUNDATION (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-1807416-A1 | NICOTINAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1682181-A2 | COMBINATION OF A VEGF RECEPTOR INHIBITOR WITH A CHEMOTHERAPEUTIC AGENT | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| EP-1667721-A2 | COMBINATIONS OF A VEGF RECEPTOR INHIBITOR WITH OTHER THERAPEUTIC AGENTS | Novartis AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006048249-A1 | NICOTINAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005027972-A2 | COMBINATION OF A VEGF RECEPTOR INHIBITOR WITH A CHEMOTHERAPEUTIC AGENT | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005027973-A2 | COMBINATIONS OF A VEGF RECEPTOR INHIBITOR WITH OTHER THERAPEUTIC AGENTS | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1259487-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2001055114-A1 | 2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2001-08-02 | — | — | WO | disclosed |